Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $3 from $22 and keeps an Outperform rating on the shares. Following Aclaris’ zunsemetinib Phase 2b RA trial having showed no signs of efficacy or dose response and Bristol Myers’ (BMY) covalent MK2 inhibitor’s failure in ankylosing spondylitis, the firm’s current view is that MK2 is no longer an attractive target to pursue in I&I. Evercore has accordingly removed zunsemetinib from its Aclaris model, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics price target lowered to $9 from $43 at H.C. Wainwright
- Aclaris Therapeutics downgraded after study failure at Cantor Fitzgerald
- Aclaris Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Aclaris Therapeutics price target lowered to $8 from $29 at BTIG
- Aclaris Therapeutics downgraded to Market Perform from Outperform at Leerink
